Insider Selling: Stephen D. Chubb Unloads 2,000 Shares of Charles River Laboratories Stock (CRL)
Charles River Laboratories (NYSE:CRL) Director Stephen D. Chubb sold 2,000 shares of the stock on the open market in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $59.18, for a total transaction of $118,360.00. Following the sale, the director now directly owns 22,365 shares in the company, valued at approximately $1,323,561. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Deutsche Bank reiterated a “hold” rating on shares of Charles River Laboratories in a research note on Wednesday, August 13th. They now have a $59.00 price target on the stock, up previously from $58.00. Separately, analysts at Credit Suisse reiterated a “neutral” rating on shares of Charles River Laboratories in a research note on Friday, August 8th. They now have a $60.00 price target on the stock, up previously from $56.00. Finally, analysts at SunTrust initiated coverage on shares of Charles River Laboratories in a research note on Tuesday, June 24th. They set a “neutral” rating and a $55.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $58.00.
Shares of Charles River Laboratories (NYSE:CRL) traded up 1.79% during mid-day trading on Thursday, hitting $61.33. 260,751 shares of the company’s stock traded hands. Charles River Laboratories has a 52-week low of $44.12 and a 52-week high of $62.50. The stock’s 50-day moving average is $56.53 and its 200-day moving average is $56.22. The company has a market cap of $2.863 billion and a price-to-earnings ratio of 24.64.
Charles River Laboratories (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.82 by $0.15. The company had revenue of $341.18 million for the quarter, compared to the consensus estimate of $327.96 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s quarterly revenue was up 16.5% on a year-over-year basis. On average, analysts predict that Charles River Laboratories will post $3.33 earnings per share for the current fiscal year.
Charles River Laboratories International, Inc is a global provider of solutions, which accelerate the early-stage drug discovery and development process.
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.